Lorundrostat

The FDA approved the phase 2 Explore-OSA trial set to assess the highly selective aldosterone synthase inhibitor, lorundrostat, in adults with obstructive sleep apnea and hypertension, according to a press release.

PHILADELPHIA — Obesity-associated dysregulated aldosterone is an endotype predictive of response to lorundrostat for patients with uncontrolled or treatment-resistant hypertension, according to data presented at ASN Kidney Week.